{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:28:17Z","timestamp":1779114497476,"version":"3.51.4"},"reference-count":130,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":1037,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1093\/annonc\/mdw534","type":"journal-article","created":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T19:05:48Z","timestamp":1475607948000},"page":"57-74","source":"Crossref","is-referenced-by-count":45,"title":["Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies"],"prefix":"10.1016","volume":"28","author":[{"given":"A.K.S.","family":"Salama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Moschos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw534_bb0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1093\/annonc\/mdw534_bb0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3902","article-title":"Immunological hallmarks of stromal cells in the tumour microenvironment","volume":"15","author":"Turley","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1093\/annonc\/mdw534_bb0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1093\/annonc\/mdw534_bb0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1093\/annonc\/mdw534_bb0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdw534_bb0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdw534_bb0040","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdw534_bb0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1093\/annonc\/mdw534_bb0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1093\/annonc\/mdw534_bb0055","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/eji.201344423","article-title":"PD-1 regulates extrathymic regulatory T-cell differentiation","volume":"44","author":"Chen","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1093\/annonc\/mdw534_bb0060","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdw534_bb0065","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw534_bb0075","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw534_bb0080","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0085","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12392","article-title":"RAC1 P29S regulates PD-L1 expression in melanoma","volume":"28","author":"Vu","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mdw534_bb0090","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdw534_bb0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"10.1093\/annonc\/mdw534_bb0100","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdw534_bb0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","article-title":"PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival","volume":"1","author":"Lipson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1093\/annonc\/mdw534_bb0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment","volume":"46","author":"D\u2019Angelo","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdw534_bb0115","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-13-2702","article-title":"In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas","volume":"20","author":"Schalper","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0120","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0125","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0130","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.9018","article-title":"Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0140","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1093\/annonc\/mdw534_bb0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0150","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0155","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.6009","article-title":"Further evaluations of nivolumab (nivo) versus investigator\u2019s choice (IC) chemotherapy for recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141","volume":"34","author":"Ferris","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0170","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0175","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0180","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0185","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0190","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw534_bb0195","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8021","article-title":"Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC","volume":"32","author":"Brahmer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0205","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.3001","article-title":"A phase 1 study of MEDI4736, an anti\u2013PD-L1 antibody, in patients with advanced solid tumors","volume":"32","author":"Lutzky","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps9086","article-title":"A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0215","series-title":"Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA).","author":"Sznol","year":"2008"},{"key":"10.1093\/annonc\/mdw534_bb0220","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3065","article-title":"A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL)","volume":"33","author":"Vey","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0225","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0230","author":"Mahadevan","year":"2011"},{"key":"10.1093\/annonc\/mdw534_bb0235","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0240","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"R\u00fcter","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdw534_bb0245","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"de Vos","year":"2014","journal-title":"J Hematol Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0250","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","article-title":"A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma","volume":"95","author":"Hussein","year":"2010","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw534_bb0255","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0260","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3079","article-title":"First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: preliminary safety and pharmacokinetic (PK)\/pharmacodynamics results","volume":"34","author":"Hamid","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0265","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps3093","article-title":"A phase I study of MEDI6383, an OX40 agonist, in adult patients with select advanced solid tumors","volume":"33","author":"Bauer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0270","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.3023","article-title":"A phase I, first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies","volume":"32","author":"Awada","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0275","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.3024","article-title":"Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies","volume":"32","author":"Ansell","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0280","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0285","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0290","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0300","unstructured":"Panel chair et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Melanoma Version 1.2017. \u00a9 2016 National Comprehensive Cancer Network, Inc. Available at NCCN.org (18 September 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdw534_bb0305","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0310","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1093\/annonc\/mdw534_bb0320","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1093\/annonc\/mdw534_bb0325","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0330","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba101","article-title":"Phase I\/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040","volume":"33","author":"El-Khoueiry","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0335","doi-asserted-by":"crossref","unstructured":"Nghiem P, Bhatia S, Daud A et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma [Abstract]. Presented at the European Cancer Congress; 25\u201329 September 2015; Vienna, Austria. Abstract 22LBA.","DOI":"10.1016\/S0959-8049(15)30074-5"},{"key":"10.1093\/annonc\/mdw534_bb0340","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw534_bb0345","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdw534_bb0350","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.29889","article-title":"Irradiation and immunotherapy: from concept to the clinic","volume":"122","author":"Salama","year":"2016","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw534_bb0355","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hed.21031","article-title":"Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer","volume":"31","author":"Albers","year":"2009","journal-title":"Head Neck"},{"key":"10.1093\/annonc\/mdw534_bb0360","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.20131889","article-title":"Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance","volume":"211","author":"Khan","year":"2014","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdw534_bb0365","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0370","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdw534_bb0375","doi-asserted-by":"crossref","first-page":"O7","DOI":"10.1186\/2051-1426-3-S2-O7","article-title":"Preliminary results from a phase I\/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers","volume":"3","author":"Gangadhar","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1093\/annonc\/mdw534_bb0380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1093\/annonc\/mdw534_bb0385","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0390","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdw534_bb0395","series-title":"A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma [Abstract]. Presented at the American Society for Clinical Oncology; May 31\u2012June 4 Chicago IL USA Abstract 9079","author":"Kudchakar","year":"2013"},{"key":"10.1093\/annonc\/mdw534_bb0400","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1093\/annonc\/mdw534_bb0405","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/pcmr.12383","article-title":"Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab","volume":"28","author":"Minor","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mdw534_bb0410","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3003","article-title":"Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and\/or MEK (trametinib) inhibitors in advanced melanoma","volume":"33","author":"Ribas","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0415","doi-asserted-by":"crossref","unstructured":"Bendell JC. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and\/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). Presented at the American Society for Clinical Oncology Gastrointestinal Cancers Symposium; January 15\u2013 17 2015; San Francisco, CA, USA. Abstract 704","DOI":"10.1200\/jco.2015.33.3_suppl.704"},{"key":"10.1093\/annonc\/mdw534_bb0420","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdw534_bb0425","doi-asserted-by":"crossref","first-page":"238ra70","DOI":"10.1126\/scitranslmed.3008211","article-title":"Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients","volume":"6","author":"Cha","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdw534_bb0430","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3061","article-title":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models","volume":"31","author":"Selby","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0435","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdw534_bb0440","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0445","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J Immunol."},{"key":"10.1093\/annonc\/mdw534_bb0450","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0455","unstructured":"Sznol M, Callahan MK, Kluger H et al. Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma. Presented at the Society for Melanoma Research; 18\u201321 November 2015; San Francisco, CA, USA."},{"key":"10.1093\/annonc\/mdw534_bb0460","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0470","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0475","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (Checkmate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0480","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Cebon JS et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort [Abstract]. Presented at the American Society for Clinical Oncology; June 3\u2013June 7 2016; Chicago, IL, USA. Abstract 9506.","DOI":"10.1200\/JCO.2016.34.15_suppl.9506"},{"key":"10.1093\/annonc\/mdw534_bb0485","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.4516","article-title":"Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)","volume":"33","author":"Hammers","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0490","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8023","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results","volume":"32","author":"Antonia","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0495","first-page":"33","article-title":"Phase I\/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032","author":"Antonia","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0500","doi-asserted-by":"crossref","unstructured":"Sampson JH. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. Presented at the American Society of Clinical Oncology; May 29\u2013June 2 2015; Chicago, IL, USA. Abstract 3010.","DOI":"10.1200\/jco.2015.33.15_suppl.3010"},{"key":"10.1093\/annonc\/mdw534_bb0505","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3002","article-title":"Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors","volume":"34","author":"Tolcher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0510","unstructured":"Rizvi NA, Gettinger SN, Goldman JW et al. Safety and efficacy of firstline nivolumab and ipilimumab in non-small cell lung cancer [Abstract]. Presented at the World Conference on Lung Cancer; 6\u20139 September 2015; Denver, CO, USA. Abstract ORAL02.05."},{"key":"10.1093\/annonc\/mdw534_bb0515","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9505","article-title":"Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-na\u00efve patients (pts) with advanced melanoma (MEL) (CheckMate 067)","volume":"34","author":"Wolchok","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0520","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1093\/annonc\/mdw534_bb0525","series-title":"Presented at ESMO","article-title":"Survival, response duration, and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent or sequenced therapy in advanced melanoma","author":"Kluger","year":"2014"},{"key":"10.1093\/annonc\/mdw534_bb0530","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1093\/annonc\/mdw534_bb0535","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9519","article-title":"Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)","volume":"34","author":"Friedman","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0540","doi-asserted-by":"crossref","unstructured":"Hodi FS, Postow MA, Chesney JA et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study [Abstract]. Presented at the American Society for Clinical Oncology; May 29\u2013June 2 2015; Chicago, IL, USA. Abstract 9004.","DOI":"10.1200\/jco.2015.33.15_suppl.9004"},{"key":"10.1093\/annonc\/mdw534_bb0545","doi-asserted-by":"crossref","unstructured":"Hodi FS, Postow MA, Chesney JA et al. Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069) [Abstract]. Presented at the American Society for Clinical Oncology; June 3\u2013June 7 2016; Chicago, IL, USA. Abstract 9518.","DOI":"10.1200\/JCO.2016.34.15_suppl.9518"},{"key":"10.1093\/annonc\/mdw534_bb0550","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1093\/annonc\/mdw534_bb0555","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","article-title":"Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy","volume":"37","author":"Hoos","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0560","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0565","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0570","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","article-title":"Ipilimumab in patients with melanoma and autoimmune disease","volume":"2","author":"Kyi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1093\/annonc\/mdw534_bb0575","doi-asserted-by":"crossref","unstructured":"Menzies AM, Johnson DB, Ramanujam S et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI) [Abstract]. Presented at the American Society for Clinical Oncology; June 3\u2013June 7 2016; Chicago, IL, USA. Abstract 9515.","DOI":"10.1200\/JCO.2016.34.15_suppl.9515"},{"key":"10.1093\/annonc\/mdw534_bb0580","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-015-0064-2","article-title":"Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis","author":"Bostwick","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1093\/annonc\/mdw534_bb0585","unstructured":"Saltz L. Perspectives on Value [plenary lecture]. Presented at the American Society of Clinical Oncology; May 29\u2013June 2 2015; Chicago, IL, USA."},{"key":"10.1093\/annonc\/mdw534_bb0590","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature."},{"key":"10.1093\/annonc\/mdw534_bb0595","doi-asserted-by":"crossref","unstructured":"Kefford R, Ribas A, Hamid O et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Presented at the American Society of Clinical Oncology; May 30\u2013June 3 2014; Chicago, IL, USA. Abstract 3005.","DOI":"10.1200\/jco.2014.32.15_suppl.3005"},{"key":"10.1093\/annonc\/mdw534_bb0600","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw534_bb0605","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw534_bb0610","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat Rev."},{"key":"10.1093\/annonc\/mdw534_bb0615","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/pcmr.12340","article-title":"PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L1 clinical trials","volume":"28","author":"Madore","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mdw534_bb0620","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw534_bb0625","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3500","article-title":"Validation of the Immunoscore (IM) as a prognostic marker in stage I\/II\/III colon cancer: results of a worldwide consortium: final analysis of 1,336 patients","volume":"34","author":"Galon","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw534_bb0630","series-title":"Immunoscore\u00ae as a predictor of response to chemotherapy in stage II and stage III colon cancer","author":"Mlecnik","year":"2015"},{"key":"10.1093\/annonc\/mdw534_bb0635","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1479-5876-11-54","article-title":"The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment","volume":"11","author":"Ascierto","year":"2013","journal-title":"J Transl Med"},{"issue":"1","key":"10.1093\/annonc\/mdw534_bb0640","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-1","article-title":"The immune score as a new possible approach for the classification of cancer","volume":"10","author":"Galon","year":"2012","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdw534_bb0645","doi-asserted-by":"crossref","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","author":"Daud","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdw534_bb0650","doi-asserted-by":"crossref","unstructured":"Loo K, Tsai KK, Pauli M et al. Novel T cell exhaustion marker to predict monotherapy PD-1 compared to combination CTLA-4 and PD-1 response in melanoma [Abstract]. Presented at the American Society for Clinical Oncology; June 3\u2013June 7 2016; Chicago, IL, USA. Abstract 9520.","DOI":"10.1200\/JCO.2016.34.15_suppl.9520"},{"key":"10.1093\/annonc\/mdw534_bb0655","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps3087","article-title":"Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies","volume":"33","author":"Hamid","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931926X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931926X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/1\/57\/31190819\/mdw534.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/1\/57\/31190819\/mdw534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:06:25Z","timestamp":1624694785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341931926X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S092375341931926X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw534","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}